



# China: Embracing Uncertainty

## And Identifying Good Opportunities

August 2022

The China Evolution Equity Strategy that I manage has what we believe is a unique design among China equity strategies. We invest in the whole of the China equity universe, excluding the top 100 largest listed companies.<sup>1</sup> The Chinese stock market has around 6,000 public companies, with fewer than 100 having a market cap above USD 30 billion. However, among mainstream China strategies, many invest around 60% of their portfolio in these mega-cap stocks. So around 60% of assets appear to be invested in less than 2% of the investment universe.<sup>2</sup> We regard this as a major disconnect in terms of diversification and breadth of opportunity.

The first objective of the China Evolution Equity Strategy is to offer a unique exposure to the approximate 98% of the opportunities that are under-explored. As a key design feature, we do not aim to invest in the top 100 Chinese mega-cap stocks. A second element of portfolio design is that we take a holistic, style-agnostic investment approach. We are not constrained by growth or value. Rather, we look for stocks that have a combination of fundamental strength and mispricing opportunities. We do this through the process of discovery, deep research, and pattern recognition.

A third feature of portfolio design is a strong focus on alpha generation. We

believe that the approximate 98% of the universe that we operate in has more mispricing opportunities and aim to identify these with a flexible investment approach.

### **Q1: Chinese equities appear to have stabilized since May. Has investor sentiment toward China turned the corner?**

Looking back over recent quarters it is clear with hindsight that Chinese equities encountered a “perfect storm.” Beijing started to tighten liquidity as far back as the second half of 2020, much earlier than the rest of the world. On top of that tighter macro policy stance, you had all the regulatory actions that took investors by surprise and that lasted throughout 2021.

At the beginning of this year, the new omicron variant of COVID-19 posed a major threat to China’s strict zero-COVID policy, plus a new round of geopolitical concerns triggered by the Russia-Ukraine conflict.

Over the past one to two months, we have started to see improvement in many aspects. The policy priority has shifted from tightening to supporting growth. We would expect a more favorable liquidity and regulatory environment for the coming quarters.



**Wenli Zheng**  
*Portfolio Manager,  
China Evolution Equity Strategy*

<sup>1</sup> By market cap.

<sup>2</sup> The 100 largest listed companies in China by market cap represent around 2% of the opportunity set in terms of the total number of companies.

As of June 30, 2022. Sources: Bloomberg Finance L.P., FactSet. Financial data and analytics provider FactSet. Copyright 2022 FactSet. All Rights Reserved.

“  
Since the low  
in mid-March,  
Chinese equities  
have clawed back  
some of their  
earlier losses.

The COVID situation has improved, and the supply chain is largely back to normal. We still see small-scale outbreaks in a few cities, which inevitably impact local service businesses. However, we think another major supply chain disruption can hopefully be avoided.

Last, rising raw material prices, which hurt the margins for many Chinese industrial companies, have started to come down. This should help the earnings growth for mid-/downstream companies in China.

Since the low in mid-March, Chinese equities have clawed back some of their earlier losses. The MSCI China Index gained 9.2% while the MSCI AC World Index fell 2.2% from March 15, 2022 to August 10, 2022.<sup>3</sup> Despite this partial recovery in relative performance, I don't get the sense that sentiment has suddenly turned overly bullish. The sense I get is that investors feel that the worst is probably behind us, and the economy should improve in the second half of the year.

**Q2: With some light at the end of the tunnel, in China's case, has the bad news largely been discounted?**

I think the Chinese economy has passed the phase of sharp deceleration seen in the first half of 2022. We do not expect large-scale stimulus, but we believe things will be improving in the coming quarters. The question is about what the slope of the improvement would look like.

One thing I want to highlight is that I think China is in a unique position when it comes to its business cycle. With inflation remaining muted at around 2.5% in June, according to government data, the central bank has enough leeway to loosen, while most other major economies are on a tightening cycle to contain high inflation rates that have not been seen in decades. This could put China's market in a relatively better position.

The result of the different economic picture can be traced back to COVID

response. In the first COVID wave, most countries responded to what was essentially a supply issue by stimulating aggregate demand. With hindsight, that's a recipe for high inflation. China, on the other hand, focused on cutting taxes for enterprises and protecting employment. The result is that supply chains and productivity are maintained, but demand has been relatively weak.

I think what's important for investors is not whether China will meet a specific gross domestic product growth target of 5.5%. Rather, it's about whether the economic situation in a broad sense is improving or deteriorating. China's equity market is broad and deep. As long as the economy stabilizes, there are ample bottom-up opportunities for investors.

**Q3: Turning to your portfolio, what changes have you made in 2022?**

We are bottom-up investors, and we don't construct the portfolio based on our macro views. We go through the whole opportunity set and try to identify stocks with the most attractive risk/reward profiles. There are three buckets where we find interesting opportunities.

The first bucket is a group of unique businesses that we believe can compound at 20%+ for the next three to five years. The sharp sell-off earlier this year offered us the opportunity to acquire some of them at an attractive price. That includes a leading EV (electric vehicle) startup, an online recruiting platform, and a shopping mall operator.

The second bucket is what we call "nonlinear growers." These are companies that we think will go through meaningful earnings acceleration driven by product cycle or operation improvement. Examples include an automotive display company and a pharmaceutical packaging company. We expect both to benefit from a sharp increase in average selling price (ASP) driven by product upgrades.

<sup>3</sup> Past performance is not a reliable indicator of future performance. Source: Bloomberg Finance L.P. and MSCI (see Additional Disclosure).



I think EV could be a major driver for China's industrial upgrade over the next five to 10 years.

— Wenli Zheng

Portfolio Manager,  
China Evolution Equity Strategy

In the third bucket are companies facing short-term margin pressures because of rising raw material prices. They are proven businesses, and we think margin pressures are likely to reverse over the next one to two years. This category includes a leading gas distributor in China as well as an instant noodle manufacturer.

On the flip side, we have also been making some disposals, including stocks that benefited from the pandemic and supply chain disruption. Their margins are at multiyear highs and could be difficult to sustain. Examples include some integrated circuit design companies, container shipping businesses, and small appliances manufacturers.

In some other cases, we are making the changes to adapt to evolving trends. For example, the structural shift in the property market and demographic change (low birth rate) could have long-term consequences for some of our holdings, and we have made some adjustments accordingly.

#### **Q4: Do you see electric vehicles as a big opportunity for investors in Chinese equities?**

I think EV could be a major driver for China's industrial upgrade over the next five to 10 years. China's auto market is seven to eight times larger than the smartphone market,<sup>4</sup> and we see similar dynamics between the two industries. China is the largest auto market globally but local original equipment manufacturers (OEMs) had a relatively weak position in internal combustion engine (ICE) cars with less than 40% market share. However, Chinese companies' position in EV is much stronger with a share in the local market of more than 80%.<sup>5</sup> Over time, we believe China auto makers could potentially play a meaningful role in global EV markets as well.

That potentially could bring huge opportunities across the whole supply

chain. Including battery makers, auto parts companies, equipment suppliers, and automation/software vendors.

Our focus in EV, besides select EV OEMs, is mainly on auto parts companies with strong competitive positioning and content gain opportunities. For example, we think there is potential for auto glass's value per car to go up two to three times over the next several years, driven by EV and innovations. Similarly for auto display, we see both rapid content gain as well as market consolidation as auto screens become larger with high specifications. Another area of content gain is auto relays, where high voltage from EVs can drive ASP two to three times higher.

The EV transition is expected to lead to rapid change in competitive landscape as well. For example, one of China's leading gearbox manufacturers has only an 8% market share in the traditional ICE market. However, for the EV market, the manufacturing process requires far greater precision, and this added complexity creates higher barriers to entry. As such, this company has achieved a 50% market share and gained a dominant market position.<sup>6</sup>

#### **Q5: Finally, what happens if a portfolio holding were to break into the ranks of the top 100 Chinese mega-cap stocks?**

The China Evolution Equity Strategy seeks to invest in potential future winners at an early stage of their life cycle. Compounders are rare, and once we find them, we hope to stay invested and let them compound value for our clients. So, we don't have to sell when our portfolio companies become mega-cap stocks. However, we constantly evaluate each position in our portfolio. There should be good reasons for the mega-cap to remain in the portfolio. They'll have to continue to meet our expected return target and still have strong growth prospects.

<sup>4</sup> T. Rowe Price ballpark estimate for illustrative purposes only, as of June 2022. Actual outcomes may differ materially from estimates. Estimates are subject to change.

<sup>5</sup> Source: T. Rowe Price analysis of industry data, as of June 2022.

<sup>6</sup> Sources: T. Rowe Price analysis, company disclosure FY2022.

---

**Risks—the following risks are materially relevant to the portfolio:**

**Country (China)**—Chinese investments may be subject to higher levels of risks such as liquidity, currency, regulatory and legal risks due to the structure of the local market.

**Currency**—Currency exchange rate movements could reduce investment gains or increase investment losses.

**Emerging markets**—Emerging markets are less established than developed markets and therefore involve higher risks.

**Small and mid-cap**—Small and mid-size company stock prices can be more volatile than stock prices of larger companies.

**Stock Connect**—Stock Connect is subject to higher regulatory, custody, and default risks as well as liquidity risk and quota limitations.

**Volatility**—the performance of the portfolio has a risk of high volatility.

**General Portfolio Risks**

**Equity**—Equities can lose value rapidly for a variety of reasons and can remain at low prices indefinitely.

**ESG and sustainability**—ESG and Sustainability risk may result in a material negative impact on the value of an investment and performance of the portfolio.

**Geographic concentration**—Geographic concentration risk may result in performance being more strongly affected by any social, political, economic, environmental or market conditions affecting those countries or regions in which the portfolio's assets are concentrated.

**Hedging**—Hedging measures involve costs and may work imperfectly, may not be feasible at times, or may fail completely.

**Investment portfolio**—Investing in portfolios involves certain risks an investor would not face if investing in markets directly.

**Management**—Management risk may result in potential conflicts of interest relating to the obligations of the investment manager.

**Market**—Market risk may subject the portfolio to experience losses caused by unexpected changes in a wide variety of factors.

**Operational**—Operational risk may cause losses as a result of incidents caused by people, systems, and/or processes.

T. Rowe Price focuses on delivering investment management excellence that investors can rely on—now and over the long term.



#### Additional Disclosure

MSCI—MSCI and its affiliates and third party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

#### Important Information

**This material is being furnished for general informational and/or marketing purposes only.** The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

**Australia**—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.

**Brunei**—This material can only be delivered to certain specific institutional investors for informational purpose upon request only. The strategy and/or any products associated with the strategy has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.

**Canada**—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.'s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.

**EEA**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Hong Kong**—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

**Indonesia**—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.

**Korea**—This material is intended only to Qualified Professional Investors upon specific and unsolicited request and may not be reproduced in whole or in part nor can they be transmitted to any other person in the Republic of Korea.

**Mainland China**—This material is provided to specific qualified domestic institutional investor or sovereign wealth fund on a one-on-one basis. No invitation to offer, or offer for, or sale of, the shares will be made in the mainland of the People's Republic of China (“Mainland China”, not including the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the Mainland China. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the Mainland China. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the Mainland China that are expressly authorized under the laws and regulations of the Mainland China to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is the official currency of the Mainland China. Potential investors who are resident in the Mainland China are responsible for obtaining the required approvals from all relevant government authorities in the Mainland China, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the Mainland China, or nationals with permanent residence in the Mainland China, or to any corporation, partnership, or other entity incorporated or established in the Mainland China.

**Malaysia**—This material can only be delivered to specific institutional investor upon specific and unsolicited request. The strategy and/or any products associated with the strategy has not been authorised for distribution in Malaysia. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.

**New Zealand**—Issued in New Zealand by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

**Philippines**—THE STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING OFFERED OR SOLD HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

**Singapore**—Issued in Singapore by T. Rowe Price Singapore Private Ltd. (UEN: 201021137E), No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

**South Africa**—T. Rowe Price International Ltd (TRPIL), 60 Queen Victoria Street, London, EC4N 4TZ, is an authorised financial services provider under the Financial Advisory and Intermediary Services Act, 2002 (Financial Services Provider (FSP) Licence Number 31935), authorised to provide “intermediary services” to South African Investors. TRPIL’s Complaint Handling Procedures are available to clients upon request. The Financial Advisory and Intermediary Services Act Ombud in South Africa deals with complaints from clients against FSPs in relation to the specific services rendered by FSPs. The contact details are noted below: Telephone: +27 12 762 5000, Web: www.faisombud.co.za, Email: info@faisombud.co.za

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**Taiwan**—This does not provide investment advice or recommendations. Nothing in this material shall be considered a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person in the Republic of China.

**Thailand**—This material has not been and will not be filed with or approved by the Securities Exchange Commission of Thailand or any other regulatory authority in Thailand. The material is provided solely to “institutional investors” as defined under relevant Thai laws and regulations. No distribution of this material to any member of the public in Thailand is permitted. Nothing in this material shall be considered a provision of service, or a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person where such provision, offer, solicitation, purchase or sale would be unlawful under relevant Thai laws and regulations.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

**USA**—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2022 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.